Table 3.

Neurological deterioration, mortality, recurrent vascular events, haemorrhagic transformation, and adverse events in patients with large artery occlusive disease

		Aspirin (n=173)	LMWH (n=180)	p
Neurological deterioration
Day 2–9		8 (5%)	10 (6%)	0·69
	Progressing stroke	8	9
	Non-stroke neurological manifestation	0	1
Day 10 to month 6
	Recurrent stroke	9 (5%)	8 (4%)	0·74
Mortality
Day 10		0 (0%)	1 (1%)	1·00
Month 6 [total patients assessed]		8 (5%) [171]	9 (5%) [179]	0·88
Other vascular events by 6 months
Acute coronary syndrome		2 (1%)	6 (3%)	0·28
Deep vein thrombosis		2 (1%)	1 (1%)	0·62
Pulmonary embolus		0 (0%)	0 (0%)	..
Haemorrhagic transformation on CT scan		7 (4%)	6 (3%)	0·72
Symptomatic		2	1
Asymptomatic		5	5
Adverse event or severe adverse events		83 (48%)	87 (48%)	0·95
Haemorrhagic adverse events		15 (9%)	25 (14%)	0·12

Data are numbers (%), unless otherwise indicated. LMWH=Low-molecular-weight heparin.